Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Core Points - Biomea Fusion, Inc. granted non-qualified stock options to a new employee for a total of 25,000 shares, vesting quarterly over four years [1][2] - The stock option award is part of Biomea's 2023 Inducement Equity Plan, adopted on November 17, 2023 [2] - Biomea is focused on developing oral covalent small molecules for diabetes, obesity, and metabolic diseases, aiming to improve patient outcomes [3][4] Company Overview - Biomea Fusion is a clinical-stage company dedicated to discovering and developing innovative medicines for diabetes and obesity [3] - The company utilizes its proprietary FUSION™ System to create next-generation covalent-binding small-molecule medicines [4] - Biomea aims to provide significant clinical benefits and potentially cure diseases for the patients it serves [4]